PM Images Shareholders of AbbVie Inc. (NYSE:ABBV) should be thrilled with its overall results, as just the appreciation over the past decade has outperformed the market. Shares of ABBV have appreciated by 248.90% over the past decade and by 104.87% over the past 5 years. The SPDR S&P 500 ETF Trust (SPY), which is what I use to track the market, has appreciated by 78.52% over the past 5 years, and by 175.83% over the past decade. ABBV is one of those companies that continues to outpace the market, and when t ...

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine-     Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment-     Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science NORTH CHI ...

AbbVie (ABBV) closed the latest trading day at $167.52, indicating a -0.89% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.The drugmaker's stock has dropped by 6.02% in the past month, falling short of the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.Investors will be eagerly watching for the performance of AbbVie in its upcoming earning ...

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally. Many small-cap biotech stocks are being held back by the Fed’s more restrictive stance on interest rates. But even some of the large-cap names with commercially available drugs that are household names are also underperforming the market. But “some” isn’t the same as “all.” In a stock picker’s market, you want to find the stocks that have a chance to outperform. One way to find thes ...

From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow® IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people w ...

Income-seeking investors can look forward to steady payout raises from these pharma stocks.If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions. Healthcare expenses are generally unavoidable, which makes it a great sector to look for stocks with steadily rising dividend payouts.AbbVie (ABBV -0.12%), Bristol Myers Squibb (BMY -0.43%), and Johnson & Johnson (JNJ -0.53%) a ...

The latest trading session saw AbbVie (ABBV) ending at $169.80, denoting a -0.12% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.03%.The drugmaker's shares have seen a decrease of 4.95% over the last month, not keeping up with the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.The upcoming earnings release of AbbVie will be of gr ...

IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on ... [+] October 17, 2023 in Irvine, California. (Photo by Mario Tama/Getty Images)Getty ImagesWe believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ. However, we think that this valuation gap will likely narrow over the coming years in favo ...

The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work. Dividend stocks are an excellent example of one such method. In fact, investors can buy dividend stocks for $50,000 per year income. Dividend stocks are one of the most reliable sources of passive income available. Investors have been using dividends to create wealth for hundreds of years, in fact several hundred years. In 1602, the Dutch East ...

Chip Somodevilla/Getty Images News Written by Sam Kovacs Introduction As dividend investors, there are three boxes which we need to tick before hitting buy on a stock: We need to like the business model and its prospects. The combination of dividend yield and our estimate of future dividend growth must be attractive. The stock needs to be undervalued. Of course there are many ramifications and details that go into these tasks, and getting it right requires skill, thought, and timeliness. But generall ...